key: cord-0775891-loxaz58o
authors: Saluzzo, Francesca; Mantegani, Paola; Poletti de Chaurand, Valeria; Cugnata, Federica; Rovere-Querini, Patrizia; Cilla, Marta; Erba, Patrizia Paola; Racca, Sara; Tresoldi, Cristina; Uberti-Foppa, Caterina; Di Serio, Clelia; Cirillo, Daniela Maria
title: Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy
date: 2021-12-23
journal: Eur Respir J
DOI: 10.1183/13993003.02099-2021
sha: 96889bde91a60d3e7f7955133181cf19ec4eed87
doc_id: 775891
cord_uid: loxaz58o

This study demonstrated that the use of point of care technologies on saliva represents a valid and highly specific solution to simplify, speed up and broadly distribute the diagnostic process for the control of the COVID-19 epidemic https://bit.ly/3oh4bds

Since the two kits employed on saliva, as well as those used on NPS, assess different target genes (Simplexa: Orf1ab and S; Xpert: N2 and E; Cobas: E and Orf1ab), we analysed, for the shared targets, the correlation between cycle threshold (Ct) values detected on saliva and on NPS.

We identified a positive correlation for Ct values detected on saliva and on NPS for Orf1ab, detected both by Simplexa performed on saliva and by Cobas on NPS (Kendall correlation 0.7704, p<0.0001) as well as for E (Kendall correlation 0.7961, p<0.0001) and N2 (Kendall correlation 0.8311, p<0.0001), both targets of the Xpert assay performed on saliva and on NPS (figure 1a). Hence, when compared to NPS, both tests on freshly collected saliva appeared to have good sensitivity and specificity as well as a positive correlation for Ct values detected for the shared targets. Both Xpert and Simplexa platforms proved to be practical and easy to use on saliva, and the obtained results demonstrated an overall performance comparable to NPS, with a specificity of 100% and a sensitivity higher than 90% for freshly collected samples and higher than 87% for samples stored at −80°C, thus demonstrating the possibility to perform these tests also on frozen samples with only a minimal loss in sensitivity. It is interesting to note that the samples comprised all the different SARS-CoV-2 variants of concern currently represented in Italy (alpha, beta and delta) and both kits' performance was not compromised by such variable.

The tests employed exhibited an overall excellent level of agreement, even when considering the differences identified once we included the biobank samples into the analysis.

As the pandemic evolves, the implementation of a testing strategy based on points of care widespread across the jurisdiction could help to guarantee a prompt on-site diagnosis, allowing the rapid identification and control of clusters and outbreaks, thus protecting the community from disease transmission. Moreover, if this new diagnostic plan would involve the use of highly reliable self-collecting samples directly at patients' homes, such as saliva, we would reduce the burden on healthcare workers, and the costs related to the use of NPS with specific transport medium. This approach would also contribute to drastically decrease the number of possible infectious individuals commuting to the sampling hubs, who could represent a major public health risk.

This diagnostic approach could be easily implemented also in low and middle income countries, where point-of-care platforms are already widely employed for the diagnosis of other illnesses, such as tuberculosis, HIV and viral hepatitis.

In conclusion, our findings support the use of saliva on point-of-care technologies as a valid solution to simplify, speed up and broadly deploy across the territory the diagnostic processes for the control of the COVID-19 epidemic. 

Commercialized diagnostic technologies to combat SARS-CoV2: advantages and disadvantages

Saliva as a gold-standard sample for SARS-CoV-2 detection

Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2

Exploring salivary diagnostics in COVID-19: a scoping review and research suggestions

Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid Xpert Xpress SARS-CoV-2

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Conflict of interest: F. Saluzzo has nothing to disclose. P. Mantegani has nothing to disclose. V. Poletti de Chaurand has nothing to disclose. F. Cugnata has nothing to disclose. P. Rovere-Querini has nothing to disclose. M. Cilla has nothing to disclose. P.P. Erba has nothing to disclose. S. Racca has nothing to disclose. C. Tresoldi has nothing to disclose. C. Uberti-Foppa has nothing to disclose. C. Di Serio has nothing to disclose. D.M. Cirillo reports provision of tests from Cepheid and DiaSorin during the conduct of the study.